ACUTE MYELOGENOUS LEUKEMIA
Two projects, now underway, aim to develop cures for this intractable disease.
ERADICATING MINIMAL RESIDUAL DISEASE IN AML
While AML often responds well to initial treatment, most patients have residual cancer cells that cause the disease to return. Too frequently, the resurgent malignancy does not respond to follow-up treatments — perhaps because of residual cells’ inherent resistance, or due to a protective niche in the micro-environment or resulting from as-yet-unknown factors. This ambitious project explores the biological mechanisms underlying minimally residual AML immediately after initial responses, seeking to identify targets for treatment strategies to keep the disease from returning.
TARGETING CLONAL HEMATOPOIESIS TO PREVENT AML
This project asks the provocative question, “Is AML preventable by intercepting the progression of its pre-malignant state, clonal hematopoiesis?” Pursuing a novel investigative strategy bringing together clinical trials and laboratory modeling, this TeamLab intends to create a new paradigm for AML management: one based on identifying individuals at greatest risk of developing the disease and on creating strategies for early detection and prevention.
MAKE A DIFFERENCE
Break Through Cancer was created in February 2021 with an extraordinary matching gift of $250,000,000. Every gift to the Foundation supports groundbreaking cancer research and helps us to meet our matching commitment.
For questions about giving please email Lisa Schwarz, Chief Philanthropy Officer at LMS@BreakThroughCancer.org